Copy to clipboard 
Amplitude Surgical reported FY 4Q20 orthopedic revenue of USD €11.8 million ($13.3 million), -54.4% vs. FY 4Q19, with full fiscal year 2020 revenue of €88.2 million, -13.9% vs. 2019. Despite a gradual resumption of surgical procedures beginning in May, the company lost significant momentum in its fiscal fourth quarter. However, by the end of June, activity for the company had normalized in all regions except Brazil and the U.S. (a key market for the company). For the fiscal year, Amplitude’s Novastep line of foot and ankle products continued its double-digit growth trajectory and grew +63% in the U.S. Novastep accounted for 9.8% of all Amplitude sales in FY 2020.
At the end of June, the company had €36 million in cash and cash equivalents including a €19.5 million line of financing from state-guaranteed loans and an Atout loan from BPI French investment bank. The reserves should let Amplitude cope with a second wave of the pandemic.
“The first eight months of the fiscal year, Amplitude continued its growth driven by the good performance of its international activity and winning new clients in France. The end of the year was marked by a substantial slowdown as a result of the COVID-19 pandemic that led to the suspension of scheduled surgical procedures.” – Amplitude Surgical CEO Olivier Jallabert
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| FY 4Q20 | FY 4Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $11.1 | $25.5 | ($14.4) | (56.5%) |
| Knees | $6.6 | $15.0 | ($8.4) | (56.3%) |
| Hips | $4.5 | $10.5 | ($6.0) | (56.7%) |
| Trauma | $1.6 | $2.2 | ($0.6) | (28.1%) |
| Sports Medicine | $0.4 | $0.9 | ($0.5) | (58.2%) |
| Orthobiologics | $0.2 | $0.6 | ($0.4) | (60.1%) |
| Total | $13.3 | $29.2 | ($15.9) | (54.4%) |
| FY 20 | FY 19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $84.5 | $101.1 | ($16.5) | (16.3%) |
| Knees | $49.8 | $59.2 | ($9.5) | (16%) |
| Hips | $34.8 | $41.8 | ($7.1) | (16.9%) |
| Trauma | $9.8 | $8.4 | $1.3 | 15.8% |
| Sports Medicine | $2.9 | $3.5 | ($0.5) | (14.9%) |
| Orthobiologics | $2.0 | $2.3 | ($0.4) | (15.4%) |
| Total | $99.2 | $115.2 | ($16.1) | (13.9%) |
Geographic Sales
| FY 4Q20 | FY 4Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $8.0 | $17.6 | ($9.7) | (54.8%) |
| International | $5.3 | $11.6 | ($6.2) | (53.9%) |
| Subsidiaries | $4.1 | $8.5 | ($4.3) | (51.3%) |
| Distributors | $1.2 | $3.1 | ($1.9) | (61.3%) |
| Total | $13.3 | $29.2 | ($15.9) | (54.4%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Amplitude Surgical reported FY 4Q20 orthopedic revenue of USD €11.8 million ($13.3 million), -54.4% vs. FY 4Q19, with full fiscal year 2020 revenue of €88.2 million, -13.9% vs. 2019. Despite a gradual resumption of surgical procedures beginning in May, the company lost significant momentum in its fiscal fourth quarter. However, by the end...
Amplitude Surgical reported FY 4Q20 orthopedic revenue of USD €11.8 million ($13.3 million), -54.4% vs. FY 4Q19, with full fiscal year 2020 revenue of €88.2 million, -13.9% vs. 2019. Despite a gradual resumption of surgical procedures beginning in May, the company lost significant momentum in its fiscal fourth quarter. However, by the end of June, activity for the company had normalized in all regions except Brazil and the U.S. (a key market for the company). For the fiscal year, Amplitude’s Novastep line of foot and ankle products continued its double-digit growth trajectory and grew +63% in the U.S. Novastep accounted for 9.8% of all Amplitude sales in FY 2020.
At the end of June, the company had €36 million in cash and cash equivalents including a €19.5 million line of financing from state-guaranteed loans and an Atout loan from BPI French investment bank. The reserves should let Amplitude cope with a second wave of the pandemic.
“The first eight months of the fiscal year, Amplitude continued its growth driven by the good performance of its international activity and winning new clients in France. The end of the year was marked by a substantial slowdown as a result of the COVID-19 pandemic that led to the suspension of scheduled surgical procedures.” – Amplitude Surgical CEO Olivier Jallabert
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| FY 4Q20 | FY 4Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $11.1 | $25.5 | ($14.4) | (56.5%) |
| Knees | $6.6 | $15.0 | ($8.4) | (56.3%) |
| Hips | $4.5 | $10.5 | ($6.0) | (56.7%) |
| Trauma | $1.6 | $2.2 | ($0.6) | (28.1%) |
| Sports Medicine | $0.4 | $0.9 | ($0.5) | (58.2%) |
| Orthobiologics | $0.2 | $0.6 | ($0.4) | (60.1%) |
| Total | $13.3 | $29.2 | ($15.9) | (54.4%) |
| FY 20 | FY 19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $84.5 | $101.1 | ($16.5) | (16.3%) |
| Knees | $49.8 | $59.2 | ($9.5) | (16%) |
| Hips | $34.8 | $41.8 | ($7.1) | (16.9%) |
| Trauma | $9.8 | $8.4 | $1.3 | 15.8% |
| Sports Medicine | $2.9 | $3.5 | ($0.5) | (14.9%) |
| Orthobiologics | $2.0 | $2.3 | ($0.4) | (15.4%) |
| Total | $99.2 | $115.2 | ($16.1) | (13.9%) |
Geographic Sales
| FY 4Q20 | FY 4Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $8.0 | $17.6 | ($9.7) | (54.8%) |
| International | $5.3 | $11.6 | ($6.2) | (53.9%) |
| Subsidiaries | $4.1 | $8.5 | ($4.3) | (51.3%) |
| Distributors | $1.2 | $3.1 | ($1.9) | (61.3%) |
| Total | $13.3 | $29.2 | ($15.9) | (54.4%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
